Asp Isotopes Inc. · NASDAQ:ASPI
Asp Isotopes — Investor Presentation (September 2024)
43 slides from Asp Isotopes's investor presentation, Sep 26, 2024
Slide 1: Corporate Overview
ASP isotopes Corporate Overview September 2024
Slide 2: Forward Looking Statements
Forward Looking Statements Forward Looking Statements, This presentation contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private ‘Securities Litigation Reform Act of 1995. Forward-loo
Slide 3: ASP Isotopes: At a Glance
ASP Isotopes: At a Glance ASPI's advanced technology leverages 20 years of R&D history to enrich isotopes in varying levels of atomic mass. Our goal is to use innovative technology to become an indispensable supplier of enriched isotopes to three multi-billion-dollar end markets. Medical 1 Opportuni
Slide 4: Target Milestones — 2024
Target Milestones — 2024 Market Milestones Operational Milestones + Secure at least 2 additional supply agreements for isotopes critical for new technologies and healtheare. Start commercial production of isotopes at our enrichment facilities in South Africa. - 2H24 + Start constructing a first isot
Slide 5: What is an Isotope?
What is an Isotope? * Isotopes are variations of atoms, the smallest units of matter that retain all the chemical properties of an element. Isotopes are forms of a chemical element with specific properties. + Atoms with the same number of protons but different numbers of neutrons are known as isotop
Slide 6: Isotope Supply Chain
Isotope Supply Chain Isotopes have one of the most severely compromised supply chains of any material in the world and are critical to many end markets including nuclear medicine, energy, food and water: + Global isotope production is dominated by Russia (85%) with the remainder produced in the Neth
Slide 7: Our Technologies
Our Technologies Aerodynamic Separation Process (ASP) The Aerodynamic Separation Process utilizes gaseous diffusion via a stationary wall centrifuge paired with proprietary flow directors to separate isotopes of varying levels of atomic mass. Quantum Enrichment (QE) Quantum enrichment technology emp
Slide 8: ASP Isotopes
ASP isotopes
Slide 9: QE Technology: Illustrative Laser System
QE Technology: Illustrative Laser System ASP isotopes
Slide 10: ASP Isotopes: Technology Highlights
ASP Isotopes: Technology Highlights = co) yy Es wy A Cost-Effective Isotope enrichment facilities using our technology can be constructed at a fraction of capital cost and time vs. traditional isotope separation facilities. Modular, Scalable Design The plants can be small in footprint and modular in
Slide 11: The Opportunity in Nuclear Medicine
The Opportunity in Nuclear Medicine ose ape ASP isotopes)"
Slide 12: The Opportunity in Nuclear Medicine
The Opportunity in Nuclear Medicine + The global medical isotope market generated $5.1 billion in 2022 and is anticipated to generate $11.4 billion by 2032.2 + Benefiting from increased regulatory approvals and R&D spend in the radiopharmaceuticals sector. GC) + Pipeline advancements have created mu
Slide 13: Nuclear Medicine: Isotopes of Interest
Nuclear Medicine: |sotopes of Interest = 2) ASP isotopes PET Lebs End Market = 7 74 Carbon-Dating & Pharmacokinetic Cc Tracing —__ > 9T>o SPECT Scan Imaging 68Ga Stable Isotopes ASP Lotopes Ine Short half-life Radioisotopes PET Scan Imaging Oncology Treatment Non-Hodgkin lymphoma, Prostate Cancer, N
Slide 14: Isotope End Markets: Molybdenum-100
Isotope End Markets: Molybdenum-100 (1°°Mo) Single-photon emission computed tomography (SPECT) al Market Size’ $4.61B SPECT scans are used to examine the function of internal organs. This imaging technique helps detect certain types of cancer. It creates a 3-dimensional image that can provide inform
Slide 15: Isotope End Markets: Ytterbium-176
Isotope End Markets: Ytterbium-176 (17°Yb) ‘Consensus Forecasts (USS) for Pluvicto Radiopharmaceutical Theranostics Global Market Size $ 1 8 b Yiterbium-176 300 ue c n Yb Global Market Size ae ame The radiopharmaceutical theranostics market is 1 0 0 ad a expected to be worth $3.43bn by 2028, growing
Slide 16: Isotope End Markets: Zinc-68
Isotope End Markets: Zinc-68 (°°Zn) Positron emission tomography 88Ga (PET) Gallium-68 Global Market Size* 68Ga Global Market Size $1.15B $127M somes Current Projected 8Ga is the Key Diagnostic for Most Lutetium and Actinium Based Drugs in Development + There are currently two FDA approved "Ga label
Slide 17: Isotope End Markets: Carbon-14
Isotope End Markets: Carbon-14 (*4C) Medical tracing Global Market size $410m pla Medical tracing is a scientific technique used to track the passage of a molecule. The technique incorporates a radioisotope through a reaction, cell, organism, biological system, or metabolic pathway. MC is used as a
Slide 18: Medical Isotopes — Timelines
Medical Isotopes — Timelines R&D Under Isotopes End-Market R&D Stage | Es ivation Coat tion | Anticipated Market Entry Technology Carbon-14 Pharma & Agrochem v v v 2024 ASP Molybdenum-100 Vv v Vv 2024 ASP Molybdenum-98 Vv v v 2024 ASP Ytterbium-176 v Vv v 2025 QE Nuclear Medicine Zinc-67/68 v = = 20
Slide 19: The Opportunity in Semiconductors
The Opportunity in Semiconductors ASP isotopes)»
Slide 20: The Opportunity in Semiconductors: Materials
The Opportunity in Semiconductors: Materials ASPI can establish itself as an indispensable part of the semiconductor supply chain. Using our proprietary technology and increasing capacity our goal is to become the world's leading supplier of enriched Silicon-28. We aim to enrich Silicon-28 content f
Slide 21: Silicon-28: Technological Breakthrough
Silicon-28: Technological Breakthrough + Electronics are relatively affordable because Silicon is cheap and abundant. But, although naturally occurring Silicon is a good conductor of electricity, it is not a good conductor of heat when it is reduced to very small sizes — and when it comes to fast co
Slide 22: Plan for Growth: Scaling into New Isotopes
Plan for Growth: Scaling into New Isotopes Iceland is a desirable location for ASPI’s expansion for several reasons. Here we expect to produce multiple enriched Isotopes supported by long-term contracts with significant partners. Planned isotopes include Silicon-28, Germanium-72 & 74, Xenon-129, Deu
Slide 23: The Opportunity in Nuclear Energy
The Opportunity in Nuclear Energy _—_—* JANTUM LEAP ENERGY ose ape ASP isotopes)»
Slide 24: The Problem is Well-Known...Solving it is not as Straightforward
The Problem is Well-Known...Solving it is not as Straightforward Global electricity production needs to double by 2050 and Net Zero targets have been set across the world + During COP28, 24 countries backed a Ministerial Declaration calling for the tripling of global nuclear energy capacity by 2050.
Slide 25: SMR (Small Modular Reactors): Next Wave in Nuclear Energy
SMR (Small Modular Reactors): Next Wave in Nuclear Energy The world is moving to a new type of nuclear reactor: SMR TerraPower's Natrium The US DOE has already committed billions of dollars to Advanced Reactor Design Program (ARDP) to facilitate and accelerate development of advanced reactors. a + M
Slide 26: HALEU Supply: A Growing Concern for SMRs
HALEU Supply: A Growing Concem for SMRs + Current commercial light water reactors use low-enriched uranium (LEU) fuel which has less than 5% 25U content. + Many SMRs and advanced reactors will require High Assay Low Enriched Uranium (HALEU) with 25U enrichment up to 19.75%. + Currently, there is no
Slide 27: Our Technology: What is Quantum Enrichment (QE)?
Our Technology: What is Quantum Enrichment (QE)? + Isotopes of every element have unique spectroscopic “signatures” defined by the electromagnetic radiation or “light” absorbed by their atoms from electron transitions. + QE separates two isotopes by taking advantage of the slight differences in the
Slide 28: Comparing and Contrasting Enrichment Methods
Comparing and Contrasting Enrichment Methods ‘Atomic Vapor laser Isotope Separation of Isotopes by Laser Gaseous Diffusion Centrifugation Seperation (AVLIS) Excitation ‘Quantum Leap Energy Low Capital, Small Size High Capital Cost | Capital 1/10 of Ditusion | Low Capital, Small Size | Low Capital, S
Slide 29: Quantum Enrichment: Real World Experience
Quantum Enrichment: Real World Experience Our team have used lasers to enrich many different metals + Uranium + Lithium (the only isotopes where results have been published) + Zirconium + Zine The separation process shown on the right is for Lithium 6 and 7 + Ametal with an atomic mass <100 + Mix of
Slide 30: Nuclear Fuel: Supply Chain and Prices
Nuclear Fuel: Supply Chain and Prices + Uranium supply has been in a state of sustained deficit since 2018, which is widening due to years of underinvestment in uranium assets, resulting in production issues from the world's largest suppliers. + Meanwhile, demand for front-end nuclear fuel (U;Og, UF
Slide 31: Implications for HALEU
Implications for HALEU If available (currently there is no Western Supplier of HALEU), HALEU would likely cost >$18,000 per Kg. Many SMR companies based their business plans assuming HALEU <$10,000 per Kg. We believe Quantum Enrichment may allow for HALEU production at significantly lower prices ver
Slide 32: Potential to Close the Loop on Nuclear Waste
Potential to Close the Loop on Nuclear Waste Depleted tails from other uranium enrichers produce nuclear waste. The management of this waste is becoming a problem. We believe that our technology can process this waste into HALEU - Potentially providing a solution to this growing environmental proble
Slide 33: Investment Overview
Investment Overview Leverage the following... Proven Proprietary Technology ASPI's advanced technologies leverage 20 years of R&D history to enrich isotopes in varying levels of atomic mass, allowing it to meet the growing demand in the Nuclear Medicine, Semiconductors, and Nuclear Energy industries
Slide 34: Appendix
Appendix ose ape ASP isotopes)
Slide 35: Current Group Structure
Current Group Structure + Mostcustomers contract through ASPI Guemsey + Intellectual property largely owned by ASPI (UK) ASP isotopes ASP Isotopes Inc. Delaware (US) NASDAQ: ASPI We plan to spin-out Quantum Leap Energy (QLE) as a separate public company and Ist the shares of QLE on a USS. national e
Slide 36: Company History
Company History October 2024 * foyoon tage sete Plant assets July 2022 ” «False an sonal 8 man and _ jarch 2023 Commenced rocienettal ‘easton fhe sma Scale Plant eed ‘sneer fat rom eon Ase amnete Nov 2023 + ASPL acquires 51% of he June 2023 ‘ASP Secures $9m Supply Contract with US Customer {or highl
Slide 37: One of the Most Experienced Laser Groups in the World
One of the Most Experienced Laser Groups in the World Our team has designed and constructed lasers for the following customers... Q MADA __lockneep mantinZ~ [dstl] & @ AIRBUS Raytheon Orbital ATK As BAE SYSTEMS * conaunos INSTRUMENTS & yg YW Bot U.S. AIR FORCE Brookhaven’ National Laboratory ASP. is
Slide 38: ASPI: Employees Demographics
ASPI: Employees Demographics We now have over 70 employees... Employees By Nationality Non South African 3% South African 97% 19% of employees have PhDs 41% of employees have advanced degrees or higher Employees By Role Radioisotope Engineering, Production and 15% distribution, 23% Plant constructio
Slide 39: ASP Isotopes: Leadership Team
ASP Isotopes: Leadership Team PAUL MANN Chairman, and CEO Co-founded ASP Isotopes in September 2021 20+ years of experience on Wall Street investing in healthcare and chemicals companies at Soros Fund Management, Highbridge Capital and Morgan Stanley. MA and MEng (Chemical Engineering) from Cambridg
Slide 40: ASP Isotopes: Senior Management
ASP Isotopes: Senior Management Xandra Van Heerden, PhD B= Head of R&D Head of Research & Development at ASP. Previously R&D Manager at a large biomedical engineering company Senior lecturer at the University of Pretoria for five years, with a focus on | chemical mass transfer processes and separati
Slide 41: ASP Isotopes: Scientific Advisors
ASP Isotopes: Scientific Advisors PROF EINAR RONANDER, PhD Be Chief Scientific Advisor = Globally recognized as a leading scientist in the field of isotope separation for medical and industrial applications + Pioneered the Molecular Laser Isotope Separation (MLIS) and the Atomic Vapour Laser Isotope
Slide 42: ASP Isotopes: Non-Executive Directors
ASP Isotopes: Non-Executive Directors PROF MIKE GORLEY, PhD Director * Director of Fusion Technology at the U.K. Atomic Energy Authority. and a visiting Professor at the University of Bristol, U.K. Mike is a well-known expert in fusion technology and fusion materials. + Previously served as a Chief
Slide 43: Data Sources
Data Sources 11. Meeting Isotope Needs and Capturing Opportunities for the Future: the 2015 Long Range Plan for the DOE Isotope Program https:/Awww ost gov/serviets/purl/1298983 3, Molybdenum-99 market Global Industry Analysis 2015-2019 and opportunity Assessment 2020-2030. Future Market Insights, 2
ASP Isotopes — Investor Presentation (September 2024) on 6ix